Watch the recording of the EHA 2023 highlights webinarAL amyloidosis, MPE, Myeloma, VideosJuly 10, 2023
MPE webinar on ASH 2024 myeloma and AL amyloidosis highlightsAL amyloidosis, MPE, Myeloma, NewsNovember 29, 2024
EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsAccess, MyelomaMay 28, 2025
The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patientsMyeloma, NewsJuly 25, 2025
A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and WalesAccess, Myeloma, NewsJuly 17, 2024
The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and WalesAccess, MyelomaJuly 9, 2024
EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma patientsAccess, Myeloma, NewsNovember 20, 2024
Join our upcoming MPE and ASCERTAIN webinar on cost-effectiveness analysisMPE, MyelomaSeptember 23, 2025
